Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03591731
Recruitment Status : Recruiting
First Posted : July 19, 2018
Last Update Posted : July 26, 2019
Sponsor:
Collaborators:
Federation Francophone de Cancerologie Digestive
GERCOR - Multidisciplinary Oncology Cooperative Group
Information provided by (Responsible Party):
Intergroupe Francophone de Cancerologie Thoracique

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 2021
Estimated Study Completion Date : September 2023